Musculoskeletal extremity injury is the most common trauma seen in civilians and combat casualties. Despite its high frequency, little is known about how to tune the immune response to maximize wound healing and prevent complications. Here, we assess the circulatory monocyte/macrophage recruitment to abnormal extremity wound healing as seen with heterotopic ossification (HO) and evaluate the role of macrophage derived Tgfβ1 in the pathogenesis and therapeutic targeting. We hypothesize that macrophage phenotype and cytokine secretion can be tuned to improve traumatic extremity wound healing.
PURPOSE:
Musculoskeletal extremity injury is the most common trauma seen in civilians and combat casualties. Despite its high frequency, little is known about how to tune the immune response to maximize wound healing and prevent complications. Here, we assess the circulatory monocyte/macrophage recruitment to abnormal extremity wound healing as seen with heterotopic ossification (HO) and evaluate the role of macrophage derived Tgfβ1 in the pathogenesis and therapeutic targeting. We hypothesize that macrophage phenotype and cytokine secretion can be tuned to improve traumatic extremity wound healing.
METHODS:
A proven musculoskeletal extremity trauma model of HO (30% total body surface area dorsal burn and Achilles tenotomy) was used. Inflammation at the injury site was followed with bioluminescent in-vivo imaging of myeloperoxidase activity and recruited inflammatory cell subpopulations were quantified using flow cytometry. Circulatory monocyte depletion was performed with intravenous injection of clodronate. Early HO was assessed histologically at 3 weeks. In-vitro cultured bone marrow derived macrophages were polarized to M1 and M2 phenotypes and expression of Tgfβ1 was analyzed on RNA and protein levels. In-vivo, TGFβ1 in macrophages and downstream signaling in HO progenitor cells was visualized with immunostaining of HO anlagen in human and mouse samples. Furthermore, a CD47 receptor activating peptide was used to attenuate macrophage Tgfβ1 activity.
RESULTS:
Extremity trauma resulted in a profound inflammatory response at the injury site with initial recruitment of circulatory inflammatory Ly6C hi monocytes peaking 3 days post injury comprising over 30% of cells. These were replaced by regenerative Ly6C low macrophages by day 14 which remained the prevalent macrophage population indicating a role in HO. Chemical ablation of circulatory monocytes with clodronate reduced recruitment of Ly6C low monocytes and F480 + /MHCII + macrophages and attenuated HO. Expression of profibrotic Tgf-β1, a cytokine commonly secreted by regenerative macrophages, was highly expressed at the injury site and co-localized with recruited macrophages in human early HO anlagen. These findings were confirmed in-vitro where Tgfβ1 expression was significantly increased in M2 polarized macrophages compared to M1. Interestingly, treatment with CD47 receptor activating peptide decreased macrophage Tgfβ1 expression in macrophages in vitro and systemic administration showed attenuation of early HO anlagen in vivo.
CONCLUSION: Our data demonstrate that recruited circulatory macrophages play an instrumental role in the inflammatory response and aberrant musculoskeletal wound healing through contribution from distinct macrophage subpopulations. Furthermore, we identify macrophage secreted TGF-β1 as a key cytokine driving HO. Systemic administration of therapeutics targeting macrophage phenotype and TGF-β1 secretion have a high potential to reduce aberrant musculoskeletal wound healing. These results uncover a novel role of macrophages in musculoskeletal wound healing and allow for new cell specific HO prevention. This macrophage targeted therapy can also be translated to additional wound healing disorders. 
PURPOSE:
The popularity and number of nipple-sparing mastectomy (NSM) being performed continues to increase. Ischemia or necrosis to the nipple areolar complex (NAC) or breast skin flap (SF) is a known complication after NSM and current management options to salvage the NAC and SF include local wound care and hyperbaric oxygen therapy
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(HBOT). However, there is a paucity of data in the literature evaluating the efficacy of (HBOT) following NSM. The purpose of this study is to determine whether HBOT prevents transformation of NAC or SF ischemia to necrosis and complete tissue loss.
METHODS:
After IRB approval, NSM's performed at a single institution from 1989 to 2015 were retrospectively reviewed, individually by breast, for analysis. All NAC and SF ischemia and/or necrosis were identified. Patient demographics, comorbidities, chemo-and radiation therapy, HBOT, and NAC and SF loss (resection or complete tissue loss) were collected. Student's t-test and chi square were used to compare demographics between cohorts, and Fisher's exact test was used to compare rates of progression to necrosis.
RESULTS:
Data for 693 breasts having undergone NSM was reviewed, 63 (9.1%) breasts incurred NAC ischemia and 51 (7.4%) incurred SF ischemia. A total 53.5% had therapeutic NSM, 10.1% received neoadjuvant chemotherapy, 40.4% received adjuvant chemotherapy, and 13.3% received adjuvant radiation therapy. Due to an overlap between NAC and SF ischemia, final cohort size consisted of 99 breasts. There were 12 NAC's and 15 skin flaps that developed necrosis and were resected. The mean age was 46.0 ± 9.2 years, BMI was 23.8 ± 3.8 kg/m 2 , 8.1% were active smokers until diagnosis, 3% had type 2 diabetes mellitus, and mean breast weight was 414 ± 212g. All patients underwent immediate breast reconstruction, of whom 79.8% had tissue expanders placed with a mean initial fill volume of 247 ± 104ml, 10.1% had tissue expanders, which were not filled during initial placement, and 10.1% received direct implant reconstruction with mean volume of 443.5 ± 207ml. HBOT was implemented for 12.7% (n = 8) of breasts with NAC ischemia and 23.5% (n = 12) with SF ischemia, while the remaining breasts received local wound care. Mean number of HBOT dives completed was 14.8 ± 3.8. Of breasts with NAC ischemia, progression to necrosis was similar whether HBOT was implemented or not (25.0% vs. 18.2%, respectively; p = 0.64). Breasts with SF ischemia and HBOT progressed to SF necrosis at a higher rate compared to those not receiving HBOT (75.0% vs 15.4%, respectively; p < 0.01).
CONCLUSION:
Hyperbaric oxygen therapy does not appear to prevent the progression of NAC or SF ischemia to necrosis as compared to patients not receiving HBOT following NSM. Although there may be a selection bias of those undergoing HBOT, the use of HBOT needs to be further delineated to support HBOT implementation following ischemia of the NAC or SF after NSM. 
